Eli Lilly's Obesity Pill Shows Cardiovascular Risk Reduction in Late-Stage Trial
Eli Lilly's obesity drug, Foundayo, demonstrated a 16% lower risk of major cardiovascular events and a 57% lower risk of death in adults with type 2 diabetes and obesity compared to insulin glargine. The drug also led to greater weight and blood sugar reduction. Lilly plans to seek U.S. approval for the drug by the end of Q2.
Tickers: $LLY
Topics: cardiovascular events drug trial results Eli Lilly Foundayo obesity treatment type 2 diabetes